<DOC>
	<DOCNO>NCT00144469</DOCNO>
	<brief_summary>This study evaluate efficacy safety combination peginterferon alfa-2a plus ribavirin treatment-naïve patient HCV genotype 1b infection , compare peginterferon alfa-2a monotherapy . Additionally , study evaluate efficacy safety combination peginterferon alfa-2a plus ribavirin patient CHC fail respond previous conventional-interferon base therapy .</brief_summary>
	<brief_title>A Study Peginterferon Alfa-2a Combination With Ribavirin Patients With Chronic Hepatitis C</brief_title>
	<detailed_description>Treatment-naïve patient randomly assign 1:1 ratio 48 week double-blind treatment subcutaneous , once-weekly injection 180 μg peginterferon alfa-2a ( 40KD ) plus either twice-daily oral ribavirin ( 600 1000mg/day ) placebo . All patient receive previous treatment conventional interferon fail respond ( suppression HCV-RNA detection limit sensitive assay ) relapse ( reversion HCV-RNA positive state suppression ) receive combination peginterferon alfa-2a ( 40KD ) plus ribavirin 48 week dosages state .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult patient quantifiable serum HCVRNA ( ≥500 IU/mL ) ) elevate serum alanine aminotransferase activity ( ≥45 IU per liter ) within six month screen liver biopsy finding consistent diagnosis chronic hepatitis C. Patients neutropenia ( few 1,500 neutrophil per cubic millimeter ) leukopenia ( few 3,000 white blood cell per cubic millimeter ) thrombocytopenia ( few 90,000 platelet per cubic millimeter ) anemia ( le 12 g hemoglobin per deciliter ) hepatitis B coinfection decompensated liver disease organ transplant creatinine clearance le 50 milliliter per minute poorly control psychiatric disease poorly control diabetes malignant neoplastic disease severe cardiac chronic pulmonary disease immunologically mediate disease retinopathy .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>